Brain-Targeted (Pro) Renin Receptor Knockdown Modulates Body Fluid Homeostasis

Theresa Cao1, Wencheng Li1, Dale Seth1, L Gabriel Navar1 and Yumei Feng1

1Department of Physiology, Tulane University School of Medicine, Tulane Hypertension and Renal Center of Excellence, New Orleans, LA, USA
2Department of Biomedical Sciences, Center for Cardiovascular Research, Colorado State University, Fort Collins, USA

Abstract

**Objectives:** The (pro) renin receptor (PRR) is highly expressed in the brain and is involved in the central regulation of blood pressure. However, the role of the brain PRR in regulating body fluid homeostasis in hypertension remains unclear. We hypothesized that the brain PRR knockdown modulates water intake, urine, and urinary sodium excretion in the context of angiotensin II (Ang II)-induced hypertension.

**Methods and Results:** Brain PRR was knocked down in non-transgenic (NT) normotensive and human renin-angiotensinogen double-transgenic (RA) mice by intracerebroventricular (ICV) injection of adeno-associated virus expressing short hairpin RNA targeting the PRR (AAV-PRR-shRNA). Water and food intake, and urinary excretion were recorded using metabolic cages. At baseline, RA mice exhibited higher water intake, food intake, urine excretion, urinary sodium excretion and potassium excretion compared to NT mice. PRR knockdown in the brain significantly decreased water and food intake, and urinary potassium and sodium excretion in RA mice, but had no such effects in NT mice. PRR knock down also decreased reactive oxygen species generation and plasma Ang II concentration in RA mice.

**Conclusion:** PRR knockdown modulates body fluid homeostasis in hypertensive RA mice, suggesting that the brain PRR plays a role in regulating body fluid homeostasis during Ang II-dependent hypertension.

Introduction

The renin-angiotensin system (RAS) has long been established as the primary mechanism of hypertension through increased levels of angiotensin (Ang) II and its subsequent effects on sympathetic activity, arterial vasoconstriction, water reabsorption and sodium retention, among other actions [1]. However, the existence of locally produced Ang II by the RAS in the brain has been a matter of debate owing to the lack of local renin [2-5]. Recent studies, however, have provided evidence that Ang II is produced in the brain [6,7] and have established an important role for brain Ang II in the secretion of the pressor agent, arginine vasopressin (AVP); thus, in addition to circulating levels of Ang II [5], brain Ang II is a contributor to hypertension.

Renin is the rate limiting enzyme that cleaves angiotensinogen, initiating a cascade that leads to the production of Ang II and subsequent regulation of water and food intake [8], AVP secretion [9], and sympathetic activation [10]. Recent studies have suggested that a new component the (pro) renin receptor (PRR) - participates in Ang II generation in vitro and in vivo [6,7,11-13] as well as AVP secretion [6,14]. We previously reported that knockdown of the PRR in human renin and angiotensinogen double-transgenic (RA) mice contributes to a decrease in blood pressure(BP) in this Ang II-dependent hypertensive model [6]. However, the effects of the PRR on metabolic rate and body fluid homeostasis during hypertension have not been explored.

In the current study, we used the RA mouse model, in which the brain RAS is known to contribute to the development of hypertension [15], to investigate the effect of brain PRR knockdown on body fluid homeostasis in Ang II-dependent hypertension.

Materials and Methods

Animals

Breeder mice singly transgenic for human renin (R) or human angiotensinogen (A) were generated at the University of Iowa Transgenic Animal Facilities (generous gifts from Dr. Curt D. Sigmund). R and A mice were bred to produce double-transgenic human renin and human angiotensinogen (RA) offspring. Only 8–10-week-old RA mice and their non-transgenic (NT) littermates were used in these experiments. All procedures were approved by the Institutional Animal Care and Use Committees of Tulane University School of Medicine and Colorado State University.

Construction and production of AAV-PRR-shRNA

Short hairpin RNA (shRNA) designed to target mouse PRR mRNA translation was ligated and cloned into an adeno-associated virus (AAV-2) vector tagged with green fluorescent protein (GFP), as described previously [6]. All vector packaging was performed by the
Brain-targeting AAV-PRR-shRNA by ICV microinjection

Mice from both RA and NT groups were anesthetized with 3% isoflurane (IsoSol; Abbo Laboratories, Chicago, IL) and continuously maintained on 1-1.5% isoflurane using a vaporizer. Mice were then placed in a stereotaxic apparatus (Stoelting Co., Wood Dale, IL) and ICV-microinjected (0.3 mm posterior to bregma, 1.0 mm to the right from midline, 3.3 mm from the top of the brain) with 200 nL of an AAV-PRR-shRNA solution (3.5 × 10^11 vector genomes (Vg)/100 nL) as previously described [6]. Mice were then returned to their home cages and allowed to recuperate for 48 hours before resuming collection of metabolic cage data; 48-hour resting periods were allowed between data-collection cycles.

Metabolic cage recordings

Mice were placed in metabolic cages for 24 hours and then returned to their home cages for a 24 hour rest period. Food allocated to each mouse was weighed at the initial time of placement and then recorded after 24 hours. The difference between the weights of food was calculated to determine food intake. Water intake (via water dispensers) and changes in body weight were also recorded similarly. Urine samples were collected after 24 hours and stored in 2-mL tubes at -20°C.

Urine electrolyte and osmolality analyses

Twenty-four–hour urine samples were collected (3x dilution factor) at baseline and 14 days after AAV-PRR-shRNA ICV injection. Urinary sodium and potassium concentrations and osmolality were measured using flame photometry. Twenty-four-hour urinary sodium and potassium excretion were calculated according to the following: mmol/24 h = mmol/L × mL/1000 mL × mL/24 h. Twenty-four–hour urinary osmolality was analyzed using the original units of mmol/kg, using a VAPRO vapor pressure Osmometer (Wescor Inc, Logan, UT).

Measurement of plasma and kidney Ang II

Ang II concentrations in plasma and kidney were measured using a previously described radioimmunoassay [16,17]. Briefly, after recording volumes and weights, kidneys from NT and RA mice obtained 14 days after AAV-GFP or AAV-PRR-shRNA injection were harvested and total RNA was isolated using a standard RNA extraction procedure with RN easy mini kit (Qiagen Technologies, Hilden, Germany). Total RNA was quantified using a Spectrophotometer (Thermo Scientific Nanodrop 2000). 200 ng total RNA was used for cDNA synthesis using cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). Specific primers for mouse PRR (Fwd: 5'-TCT CTC CGA ACT GCA AGT GCA ACA-3'; Rev: 5'-CCA AAC CTG CCA GCT CCA ATG AAA-3') and internal control mouse GAPDH (Fwd: 5'-AAT GTG TCC TTC TCT T-3') were designed using Primer Quest Software (Integrated DNA Technologies, Coralville, IA). Real-time reverse transcription PCR was performed using the SYBR green qPCR master mix (USB Corporation, Cleveland, OH) following the manufacturer's instruction. Cycling conditions were 95°C for 10 min and then 40 cycles consisting of 15 sec at 95°C, 60 sec at 60°C and 30 sec at 72°C. Relative expression was calculated using the 2^-ΔΔCT method. Values were expressed as the ratio to NT mice with control virus administration. The expression levels of targeted mRNAs were normalized based on the expression levels of GAPDH mRNA.

RNA isolation and real-time reverse transcription PCR

Kidney and heart from NT and RA mice 14 days after AAV-GFP or AAV-PRR-shRNA injection were harvested and total RNA was isolated using a standard RNA extraction procedure with RN easy mini kit (Qiagen Technologies, Hilden, Germany). Total RNA was quantified using a Spectrophotometer (Thermo Scientific Nanodrop 2000). 200 ng total RNA was used for cDNA synthesis using cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). Specific primers for mouse PRR (Fwd: 5'-TCT CTC CGA ACT GCA AGT GCA ACA-3'; Rev: 5'-CCA AAC CTG CCA GCT CCA ATG AAA-3') and internal control mouse GAPDH (Fwd: 5'-AAT GTG TCC TTC TCT T-3') were designed using Primer Quest Software (Integrated DNA Technologies, Coralville, IA). Real-time reverse transcription PCR was performed using the SYBR green qPCR master mix (USB Corporation, Cleveland, OH) following the manufacturer's instruction. Cycling conditions were 95°C for 10 min and then 40 cycles consisting of 15 sec at 95°C, 60 sec at 60°C and 30 sec at 72°C. Relative expression was calculated using the 2^-ΔΔCT method. Values were expressed as the ratio to NT mice with control virus administration. The expression levels of targeted mRNAs were normalized based on the expression levels of GAPDH mRNA.

Statistical analysis

Data were expressed as means ± SEM and analyzed by Student's t test, two-way, or one-way analysis of variance (ANOVA) with Bonferroni post hoc tests to compare replicate means, as appropriate. Statistical comparisons were performed using Prism5 (Graph Pad Software). Differences were considered statistically significant at P<0.05.
**Results**

**Brain-targeted PRR knockdown decreases BP in RA mice**

As showed in Figure 1A, baseline mean arterial pressure (MAP) was significantly higher in RA mice (145.3 ± 4.28) than in NT mice (108.7 ± 2.99 mmHg). PRR knockdown significantly decreased MAP in RA mice 2 weeks after AAV-PRR-shRNA injection, reducing it from baseline levels (145.3 ± 4.28 mmHg) to 124.2 ± 4.71 mmHg. However, MAP remained significantly higher in AAV-PRR-shRNA-injected RA mice compared to NT mice ICV-injected with AAV-PRR-shRNA (100.2 ± 6.31 mmHg). Notably, PRR knockdown had no effect on BP in NT mice.

![Figure 1: Effect of PRR knockdown on BP, water and food intake, and body weight. (A) MAP of NT and RA mice at baseline and 14 days after ICV injection of AAV-PRR-shRNA. (B) Water intake by NT and RA mice at baseline and 14 days after ICV injection of AAV-PRR-shRNA. (C) Food intake by NT and RA mice at baseline and 14 days after ICV injection of AAV-PRR-shRNA. (D) Body weight of NT and RA mice at baseline and 14 days after ICV injection of AAV-PRR-shRNA. (n=6/group; *P<0.05 vs. NT baseline, #P<0.05 vs. RA baseline).](image-url)

**Brain-targeted PRR knockdown reduces food and water intake in RA mice**

As shown in Figure 1B, baseline water intake by RA mice (5.44 ± 0.56 mL/24 h) was higher than that in NT mice (2.60 ± 0.45 mL/24 h). ICV delivery of AAV-PRR-shRNA significantly reduced 24 hour water intake in RA mice (3.28 ± 0.57 mL/24 h) compared to baseline values, although water intake remained higher than that in NT mice receiving AAV-PRR-shRNA (1.42 ± 0.28 mL/24 h). Interestingly, food intake at baseline was higher in RA mice (2.63 ± 0.52 g/24 h) than in NT mice (0.99 ± 0.27 g/24 h; Figure 1C). ICV injection of AAV-PRR-shRNA normalized food intake in RA, restoring it to a level that was not significantly different from that in NT mice (1.95 ± 0.46 vs. 1.18 ± 0.136 g/24 h). Despite increased daily food intake in RA mice, body weight (Figure 1D) was not significantly different between RA mice (22.80 ± 1.19 g) and NT mice (23.96 ± 1.21 g) at baseline. ICV injection of AAV-PRR-shRNA did not alter body weight in RA or NT mice (21.07 ± 1.12 vs. 20.52 ± 1.33 g).

**Effects of brain-targeted PRR knockdown on body fluid homeostasis during Ang II-dependent hypertension**

Urine excretion was higher in RA mice (3.33 ± 0.54 mL/24 h) than in NT mice (1.88 ± 0.09 mL/24 h) at baseline (Figure 2A, day 0). This increase in urine volume was associated a significant decrease in urine osmolality in RA mice (913.3 ± 85.33 mmol/kg; Figure 2B) compared to NT mice (1376 ± 89.76 mmol/kg). ICV-delivered AAV-PRR-shRNA produced a trend toward decreased urine excretion in RA mice on day 11, but this difference did not reach significance. AAV-PRR-shRNA had no effect on osmolality in RA or NT mice. Baseline urinary sodium concentration was lower in RA mice than in NT mice (0.063 ± 0.007 vs. 0.104 ± 0.004 mM); potassium concentration was similarly decreased in RA mice (0.142 ± 0.015 mM) compared to NT mice (0.197 ± 0.019 mM). AAV-PRR-shRNA had no effect on urinary sodium or potassium concentration (Figure 2C and 2D).

![Figure 2: Effects of brain-targeted PRR knockdown on body fluid homeostasis. (A) Twenty-four-hour urinary excretion in NT and RA mice at baseline (day 0) and after ICV injection of AAV-PRR-shRNA. (B) Urinary osmolality in NT and RA mice at baseline and after ICV injection of AAV-PRR-shRNA. (C) Urinary sodium concentration in NT and RA mice at baseline and after ICV injection of AAV-PRR-shRNA. (D) Urinary potassium concentration in NT and RA mice at baseline and after ICV injection of AAV-PRR-shRNA.](image-url)
Twenty-four–hour urinary sodium excretion in NT and RA mice at baseline and after ICV injection of AAV-PRR-shRNA. (F) Twenty-four–hour urinary sodium excretion in NT and RA mice at baseline and after ICV injection of AAV-PRR-shRNA. (n=6/group; *P<0.05 vs. NT).

Interestingly, urinary sodium and potassium excretion were greater in RA mice (0.22 ± 0.03 and 0.46 ± 0.07 mmol/24 h, respectively) than in NT mice (0.17 ± 0.01 and 0.31 ± 0.02 mmol/24 hours, respectively) at baseline. AAV-PRR-shRNA completely normalized this increase in urinary sodium and potassium excretion beginning 7 days after ICV injection.

Effects of brain-targeted PRR knockdown on plasma and kidney Ang II levels

We previously reported that ICV delivery of AAV-PRR-shRNA decreases Ang II levels in the hypothalamus of RA mice [18] in association with a decrease in BP [6]. To determine the effect of brain-targeted PRR knockdown outside the brain, we measured plasma and kidney Ang II levels. In RA mice treated with control virus, Ang II levels were significantly elevated in the plasma (446.2 ± 163.2 fmol/mL) and the kidney (1673 ± 130.8 fmol/g) compared to NT mice injected with control virus (Figure 3A and B). Brain-targeted PRR knockdown decreased Ang II levels in the plasma (136.2 ± 37.5 fmol/mL vs. RA+AAV-GFP), but not in the kidneys of RA mice. ICV injection of AAV-PRR-shRNA had no effect on Ang II levels in the plasma or kidney in NT mice.

Figure 3: Brain-targeted PRR knockdown decreases plasma Ang II levels. (A) Plasma Ang II levels in NT and RA mice 14 days after AAV-GFP or AAV-PRR-shRNA treatment. (B) Kidney Ang II levels in NT and RA mice 14 days after AAV-GFP or AAV-PRR-shRNA treatment. (n=6/group; *P<0.05 vs. NT-GFP, #P<0.05 vs. RA-GFP).

ICV delivery of AAV-PRR-shRNA reduces oxidative stress in the subfornical organ of RA mice

To determine whether the altered body fluid homeostasis in RA mice was associated with increased oxidative stress in the CNS, we examined fluorescence of the reactive oxygen probe, DHE, throughout the brain. Following treatment with control (AAV-GFP) vector, DHE fluorescence, measured as relative fluorescence units (RFU), was higher in the subfornical organ (SFO) of RA mice (1.8 ± 0.2-fold) than in that of NT mice, where only low-level DHE staining was observed (Figure 4A and B). Brain-targeted PRR knockdown significantly attenuated the increase in DHE fluorescence in the SFO of RA mice (fold change in RFU: 1.3 ± 0.2 vs. RA+AAV-GFP). In contrast, AAV-PRR-shRNA had no effect on DHE fluorescence in NT mice.

Figure 4: ICV delivery of AAV-PRR-shRNA reduces oxidative stress in the SFO of RA mice. (A) Representative DHE staining in the SFO of NT and RA mice 14 days after AAV-GFP or AAV-PRR-shRNA treatment. (B) Quantification of DHE staining in NR and RA mice 14 days after AAV-GFP or AAV-PRR-shRNA treatment. (n=6/group; *P<0.05 vs. NT-GFP, #P<0.05 vs. RA-GFP).

ICV injection of AAV-PRR-shRNA has no effect on PRR mRNA levels in the kidney and heart

We previously reported that ICV delivery of AAV-PRR-shRNA reduced the PRR mRNA levels in the SFO without affecting PRR expression in other brain nuclei including the paraventricular nucleus or supraoptic nucleus [6]. To investigate whether ICV injection of AAV-PRR-shRNA affects PRR expression in other peripheral organs, PRR mRNA was measured in the kidney and heart after ICV injection of AAV-GFP or AAV-PRR-shRNA in NT and RA mice. PRR mRNA levels were increased in the kidney (Figure 5A) and heart (Figure 5B) of the RA mice when treated with AAV-GFP compared to NT mice with the same treatment. ICV injection of AAV-PRR-shRNA did not affect PRR mRNA in the kidney and heart in either RA or NT mice.

Figure 5: ICV injection of AAV-PRR-shRNA has no effect on PRR mRNA levels in the kidney and heart. We previously reported that ICV delivery of AAV-PRR-shRNA reduced the PRR mRNA levels in the SFO without affecting PRR expression in other brain nuclei including the paraventricular nucleus or supraoptic nucleus [6]. To investigate whether ICV injection of AAV-PRR-shRNA affects PRR expression in other peripheral organs, PRR mRNA was measured in the kidney and heart after ICV injection of AAV-GFP or AAV-PRR-shRNA in NT and RA mice. PRR mRNA levels were increased in the kidney (Figure 5A) and heart (Figure 5B) of the RA mice when treated with AAV-GFP compared to NT mice with the same treatment. ICV injection of AAV-PRR-shRNA did not affect PRR mRNA in the kidney and heart in either RA or NT mice.

Figure 5: ICV injection of AAV-PRR-shRNA has no effect on PRR mRNA levels in the kidney and heart. (n=6/group; *P<0.05 vs. NT-GFP, #P<0.05 vs. RA-GFP).
Figure 5: ICV injection of AAV-PRR-shRNA has no effect on PRR mRNA levels in the kidney or heart. (A) PRR mRNA levels in the kidney of RA and NT mice 14 days after ICV injection of AAV-GFP or AAV-PRR-shRNA. (B) PRR mRNA levels in the heart of RA and NT mice 14 days after ICV injection of AAV-GFP or AAV-PRR-shRNA. (n=5/group; *P<0.05 vs. NT-GFP).

Discussion

Increases in brain Ang II are associated with an increase in metabolic rate in mice [19]. Consistent with this, metabolic rates in hypertensive mice through activation of the brain RAS are higher than those in normotensive mice [20]. In the current study, we found that hypertensive RA mice exhibited greater food and water intake, whereas, their body weights were similar to those of NT mice. Although resting metabolic rates were not measured in these mice, we would predict that metabolic rates are higher in RA mice. We previously reported that PRR deletion in the brain prevents Ang II formation and thus activation of the brain RAS [6,7]. Importantly, selective PRR knockdown in the brain significantly reduced food and water intake in hypertensive RA mice, suggesting the functional importance of the PRR and brain RAS in the regulation of food intake. This finding is in agreement with a previous report from Grobe and colleagues that activation of the brain RAS is essential for increasing metabolism [21]. In contrast, PRR knockdown did not affect the homeostasis in normotensive mice. These findings are consistent with previous study showing that PRR knockdown in the brain did not change the blood pressure in normotensive mice [6]. No effect of PRR knockdown on body fluid homeostasis in normotensive mice was possibly due to the redundant mechanisms in maintaining normal homeostasis in physiological conditions.

Urine excretion is regulated by multiple components of the renin-angiotensin-aldosterone system, including the renal sympathetic nervous system [22], plasma aldosterone [23], plasma Ang II [24], and AVP excretion [25-28]. We previously reported that brain-targeted PRR knockdown decreases plasma AVP levels [6], which would suggest that the urinary volume excreted should be higher. However, total urine excretion remained similar before and after brain-targeted PRR knock down, possibly due to the reduction in water intake in RA mice after PRR knock down. Sodium excretion is regulated by intrarenal pressure, the intrarenal RAS, and the renal sympathetic system [27,29,30]. Interestingly, we unexpectedly found a reduction in plasma Ang II levels following PRR knockdown with no alteration in kidney Ang II levels. It is possible that the reduction in plasma Ang II is related to a reduction in renal sympathetic activity, consistent with our previous report that PRR knockdown in the brain reduces cardiac and vasomotor sympathetic tone [6]. Thus, the reduction in BP following PRR knockdown may be a major contributor to the reduction in 24 hour sodium and potassium excretion.

Reactive oxygen species (ROS) generation has been identified as an important signaling mechanism in Ang II action. Overproduction of ROS in the vasculature has been implicated in the pathogenesis of hypertension caused by systemic Ang II infusion [31]. In the CNS, ROS are best known for their role in the pathogenesis of primary neurodegenerative diseases, such as amyotrophic lateral sclerosis [32] and Alzheimer’s disease [33]. However, Zimmerman and colleagues have reported the involvement of ROS as second messengers in Ang II-induced signaling in the CNS [34]. Using adeno-associated vector-mediated expression of superoxide dismutase (AdSOD), they found that injection of Ang II elicited changes in BP, heart rate, and drinking in the CNS-changes that were abolished by prior treatment with AdSOD. A subsequent study demonstrated that chronic infusion of Ang II over a 2-week period was correlated with marked elevations in ROS production specifically in the SFO [35]. More importantly, ICV injection of AdSOD decrease sdROS formation in the SFO and was associated with attenuation of hypertension induced by Ang II infusion. Collectively, these results suggest that ROS is an important downstream signal for brain Ang II regulation of BP and drinking responses. In our previous report, we found that Ang II levels in the hypothalamus were decreased in RA mice after PRR knockdown [18]. This decrease in Ang II levels may contribute to the reduction in ROS formation observed in current study, placing ROS in a position to act as the mediator between PRR knockdown and body fluid homeostasis in RA mice.

In summary, the brain PRR affects metabolic rate and body fluid homeostasis in Ang II-dependent hypertensive mice through regulation of Ang II, ROS, and AVP formation. These data suggest that the PRR plays a regulatory role in body fluid homeostasis during hypertension.

Acknowledgements

We thank Dr. Curt D. Sigmund from the University of Iowa for the generous gift of transgenic mice.

Sources of Funding

The work was supported in part by a grant from the American Heart Association (11SDG7360050) to Y. Feng and by the COBRE grant from NIGMS (P30GM103337) to L.G. Navar.

References
